Insulin lispro + insulin lispro protamine

Generic Medicine Info
Hypersensitivity. Hypoglycaemic episodes.
Special Precautions
Patient with chronic diabetes, recurrent hypoglycaemia, diabetic nerve disease, risk for hypokalaemia or with illness or emotional disturbances. Increased work or exercise without eating and changes in meal pattern or level of physical activity. Changes in insulin strength, brand, type and/or administration method may lead to abnormal glycaemic control and predispose to hypo- or hyperglycaemia. Renal and hepatic impairment. Pregnancy and lactation. Patient Counselling This drug may cause hypoglycaemia which may impair ability to concentrate and react, if affected, do not drive or operate machinery. Rotate injection sites within the same region to reduce risk of lipodystrophy. Monitoring Parameters Monitor blood glucose, HbA1C twice a year or quarterly, renal and hepatic function, weight, serum K (as necessary), and signs and symptoms of hypoglycaemia.
Adverse Reactions
Significant: Hypoglycaemia. Injury, poisoning and procedural complications: Local allergy at injection site including redness, swelling and itching, lipodystrophy. Investigations: Weight gain. Metabolism and nutrition disorders: Oedema. Skin and subcutaneous tissue disorders: Pruritus, rash.
Potentially Fatal: Severe hypoglycaemia, hypokalaemia. Severe allergic reactions, including anaphylaxis.
Drug Interactions
Concomitant use with peroxisome proliferator-activated receptor (PPAR)-γ agonists (e.g. pioglitazone, rosiglitazone) may cause dose-related fluid retention which may exacerbate or lead to cardiac failure. May increase risk of hypoglycaemia when given with other antidiabetic agents, antihypertensive agents (e.g. ACE inhibitors, angiotensin II receptor blockers, β-blockers), certain SSRIs (e.g. fluoxetine) or MAOIs, salicylates, somatostatin analogue (e.g. octreotide), pramlintide, and sulfonamide antibiotics. Decreased therapeutic effect with corticosteroids, danazol, diuretics, oestrogens or oral contraceptives, sympathomimetic agents (e.g. terbutaline, epinephrine), and thyroid hormones. Signs and symptoms of hypoglycaemia may be masked by β-blockers, clonidine, guanethidine and reserpine.
ATC Classification
A10AB04 - insulin lispro ; Belongs to the class of fast-acting insulins and analogues. Used in the treatment of diabetes.
A10AC04 - insulin lispro ; Belongs to the class of intermediate-acting insulins and analogues. Used in the treatment of diabetes.
A10AD04 - insulin lispro ; Belongs to the class of intermediate-acting combined with fast-acting insulins and analogues. Used in the treatment of diabetes.
Disclaimer: This information is independently developed by CIMS based on insulin lispro + insulin lispro protamine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in